In today’s rigorous health care environment, new products must present a high profit and value proposition to potential investors and acquirers. One often-overlooked aspect of profitability is whether or not the new product will be reimbursed by payers, as acceptance of the product can often be linked to reimbursement by payers, not efficacy. As a result, companies must plan their reimbursement strategies early in the product life cycle and allocate sufficient capital and resources to meet reimbursement objectives.
Please join Foley and industry leaders as they address the economics and strategies for product reimbursement, including:
Proper planning for product pricing
Preparing comparative effectiveness data
Data that should be in place for partnering or acquisition deals
Medicare product coverage strategy
Working with payer expectations
Guest Panelists Anita Chawla, Ph.D., Vice President, Analysis Group Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals
Foley Panelists Antoinette Konski, Partner and member, Chemical, Biotechnology & Pharmaceutical Practice and the Life Sciences Industry Team Judith Waltz, Partner and co-chair, Life Sciences Industry Team
This event is intended for in-house counsel and those investing in the biotech field.
Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of one General credit(s). Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must be in attendance on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event.
